The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Oral anticoagulant therapy is routinely given to most patients who have had episodes of venous thromboembolism. Two recent multicenter trials have demonstrated that if the duration of treatment after a first episode of thromboembolism is extended to three to six months, instead of four to six weeks,...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1997-02, Vol.336 (6), p.393-398 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 398 |
|---|---|
| container_issue | 6 |
| container_start_page | 393 |
| container_title | The New England journal of medicine |
| container_volume | 336 |
| creator | Schulman, Sam Granqvist, Staffan Holmström, Margareta Carlsson, Anders Lindmarker, Per Nicol, Peter Eklund, Sven-Gunnar Nordlander, Sune Lärfars, Gerd Leijd, Barbro Linder, Olle Loogna, Enno Walter, Hans Viering, Stanka Hjorth, Martin Boberg, Jonas |
| description | Oral anticoagulant therapy is routinely given to most patients who have had episodes of venous thromboembolism. Two recent multicenter trials have demonstrated that if the duration of treatment after a first episode of thromboembolism is extended to three to six months, instead of four to six weeks, the rate of recurrence can be reduced, especially among patients with permanent risk factors such as thromboembolism that was idiopathic in nature and venous insufficiency.
1
,
2
The optimal duration of secondary prophylaxis after a second episode of venous thromboembolism is unknown. In one study, patients were stratified according to whether the episode of . . . |
| doi_str_mv | 10.1056/NEJM199702063360601 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_439112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11002566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-16add7f8036ba226c6cc1249c747518b7140f2f8363463175316ab2971f6c8833</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouK7-Ai9BvEk1X03a46LrF6t7cPXiIaTZRLu2TU1aZP-9WbrsSRwYZhie9-VlADjF6BKjlF89Tx-fcJ4LRBCnlCOO8B4Y4ZTShDHE98EIIZIlTOT0EByFsEKxMMtH4H3xaeBN71VXugY6C-deVXDSdKV26qOvVNPBiHjVrqGynfFQwRejXbOE07YMbmk2ojfTuD5E0Lu6cCZ2VYb6GBxYVQVzsp1j8Ho7XVzfJ7P53cP1ZJboVKRdgrlaLoXNEOWFIoRrrjUmLNeCiRRnhcAMWWIzyinjFIuURkVBcoEt11lG6Rgkg2_4MW1fyNaXtfJr6VQpt6evuBnJaI4xifzZwLfeffcmdHLlet_EiJIQmgtCmYgQHSDtXQje2J0tRnLzdPnH06PqfGutglaV9arRZdhJSco3ESJ2MWB1HWRjVvW_pr8rgow8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223972347</pqid></control><display><type>article</type><title>The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Schulman, Sam ; Granqvist, Staffan ; Holmström, Margareta ; Carlsson, Anders ; Lindmarker, Per ; Nicol, Peter ; Eklund, Sven-Gunnar ; Nordlander, Sune ; Lärfars, Gerd ; Leijd, Barbro ; Linder, Olle ; Loogna, Enno ; Walter, Hans ; Viering, Stanka ; Hjorth, Martin ; Boberg, Jonas</creator><creatorcontrib>Schulman, Sam ; Granqvist, Staffan ; Holmström, Margareta ; Carlsson, Anders ; Lindmarker, Per ; Nicol, Peter ; Eklund, Sven-Gunnar ; Nordlander, Sune ; Lärfars, Gerd ; Leijd, Barbro ; Linder, Olle ; Loogna, Enno ; Walter, Hans ; Viering, Stanka ; Hjorth, Martin ; Boberg, Jonas ; the Duration of Anticoagulation Trial Study Group</creatorcontrib><description>Oral anticoagulant therapy is routinely given to most patients who have had episodes of venous thromboembolism. Two recent multicenter trials have demonstrated that if the duration of treatment after a first episode of thromboembolism is extended to three to six months, instead of four to six weeks, the rate of recurrence can be reduced, especially among patients with permanent risk factors such as thromboembolism that was idiopathic in nature and venous insufficiency.
1
,
2
The optimal duration of secondary prophylaxis after a second episode of venous thromboembolism is unknown. In one study, patients were stratified according to whether the episode of . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199702063360601</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiovascular disease ; Drug therapy ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>The New England journal of medicine, 1997-02, Vol.336 (6), p.393-398</ispartof><rights>Copyright © 1997 Massachusetts Medical Society. All rights reserved.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-16add7f8036ba226c6cc1249c747518b7140f2f8363463175316ab2971f6c8833</citedby><cites>FETCH-LOGICAL-c575t-16add7f8036ba226c6cc1249c747518b7140f2f8363463175316ab2971f6c8833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199702063360601$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199702063360601$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2563911$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1937955$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Schulman, Sam</creatorcontrib><creatorcontrib>Granqvist, Staffan</creatorcontrib><creatorcontrib>Holmström, Margareta</creatorcontrib><creatorcontrib>Carlsson, Anders</creatorcontrib><creatorcontrib>Lindmarker, Per</creatorcontrib><creatorcontrib>Nicol, Peter</creatorcontrib><creatorcontrib>Eklund, Sven-Gunnar</creatorcontrib><creatorcontrib>Nordlander, Sune</creatorcontrib><creatorcontrib>Lärfars, Gerd</creatorcontrib><creatorcontrib>Leijd, Barbro</creatorcontrib><creatorcontrib>Linder, Olle</creatorcontrib><creatorcontrib>Loogna, Enno</creatorcontrib><creatorcontrib>Walter, Hans</creatorcontrib><creatorcontrib>Viering, Stanka</creatorcontrib><creatorcontrib>Hjorth, Martin</creatorcontrib><creatorcontrib>Boberg, Jonas</creatorcontrib><creatorcontrib>the Duration of Anticoagulation Trial Study Group</creatorcontrib><title>The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism</title><title>The New England journal of medicine</title><description>Oral anticoagulant therapy is routinely given to most patients who have had episodes of venous thromboembolism. Two recent multicenter trials have demonstrated that if the duration of treatment after a first episode of thromboembolism is extended to three to six months, instead of four to six weeks, the rate of recurrence can be reduced, especially among patients with permanent risk factors such as thromboembolism that was idiopathic in nature and venous insufficiency.
1
,
2
The optimal duration of secondary prophylaxis after a second episode of venous thromboembolism is unknown. In one study, patients were stratified according to whether the episode of . . .</description><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiovascular disease</subject><subject>Drug therapy</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1LxDAQhoMouK7-Ai9BvEk1X03a46LrF6t7cPXiIaTZRLu2TU1aZP-9WbrsSRwYZhie9-VlADjF6BKjlF89Tx-fcJ4LRBCnlCOO8B4Y4ZTShDHE98EIIZIlTOT0EByFsEKxMMtH4H3xaeBN71VXugY6C-deVXDSdKV26qOvVNPBiHjVrqGynfFQwRejXbOE07YMbmk2ojfTuD5E0Lu6cCZ2VYb6GBxYVQVzsp1j8Ho7XVzfJ7P53cP1ZJboVKRdgrlaLoXNEOWFIoRrrjUmLNeCiRRnhcAMWWIzyinjFIuURkVBcoEt11lG6Rgkg2_4MW1fyNaXtfJr6VQpt6evuBnJaI4xifzZwLfeffcmdHLlet_EiJIQmgtCmYgQHSDtXQje2J0tRnLzdPnH06PqfGutglaV9arRZdhJSco3ESJ2MWB1HWRjVvW_pr8rgow8</recordid><startdate>19970206</startdate><enddate>19970206</enddate><creator>Schulman, Sam</creator><creator>Granqvist, Staffan</creator><creator>Holmström, Margareta</creator><creator>Carlsson, Anders</creator><creator>Lindmarker, Per</creator><creator>Nicol, Peter</creator><creator>Eklund, Sven-Gunnar</creator><creator>Nordlander, Sune</creator><creator>Lärfars, Gerd</creator><creator>Leijd, Barbro</creator><creator>Linder, Olle</creator><creator>Loogna, Enno</creator><creator>Walter, Hans</creator><creator>Viering, Stanka</creator><creator>Hjorth, Martin</creator><creator>Boberg, Jonas</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>19970206</creationdate><title>The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism</title><author>Schulman, Sam ; Granqvist, Staffan ; Holmström, Margareta ; Carlsson, Anders ; Lindmarker, Per ; Nicol, Peter ; Eklund, Sven-Gunnar ; Nordlander, Sune ; Lärfars, Gerd ; Leijd, Barbro ; Linder, Olle ; Loogna, Enno ; Walter, Hans ; Viering, Stanka ; Hjorth, Martin ; Boberg, Jonas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-16add7f8036ba226c6cc1249c747518b7140f2f8363463175316ab2971f6c8833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiovascular disease</topic><topic>Drug therapy</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schulman, Sam</creatorcontrib><creatorcontrib>Granqvist, Staffan</creatorcontrib><creatorcontrib>Holmström, Margareta</creatorcontrib><creatorcontrib>Carlsson, Anders</creatorcontrib><creatorcontrib>Lindmarker, Per</creatorcontrib><creatorcontrib>Nicol, Peter</creatorcontrib><creatorcontrib>Eklund, Sven-Gunnar</creatorcontrib><creatorcontrib>Nordlander, Sune</creatorcontrib><creatorcontrib>Lärfars, Gerd</creatorcontrib><creatorcontrib>Leijd, Barbro</creatorcontrib><creatorcontrib>Linder, Olle</creatorcontrib><creatorcontrib>Loogna, Enno</creatorcontrib><creatorcontrib>Walter, Hans</creatorcontrib><creatorcontrib>Viering, Stanka</creatorcontrib><creatorcontrib>Hjorth, Martin</creatorcontrib><creatorcontrib>Boberg, Jonas</creatorcontrib><creatorcontrib>the Duration of Anticoagulation Trial Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schulman, Sam</au><au>Granqvist, Staffan</au><au>Holmström, Margareta</au><au>Carlsson, Anders</au><au>Lindmarker, Per</au><au>Nicol, Peter</au><au>Eklund, Sven-Gunnar</au><au>Nordlander, Sune</au><au>Lärfars, Gerd</au><au>Leijd, Barbro</au><au>Linder, Olle</au><au>Loogna, Enno</au><au>Walter, Hans</au><au>Viering, Stanka</au><au>Hjorth, Martin</au><au>Boberg, Jonas</au><aucorp>the Duration of Anticoagulation Trial Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism</atitle><jtitle>The New England journal of medicine</jtitle><date>1997-02-06</date><risdate>1997</risdate><volume>336</volume><issue>6</issue><spage>393</spage><epage>398</epage><pages>393-398</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Oral anticoagulant therapy is routinely given to most patients who have had episodes of venous thromboembolism. Two recent multicenter trials have demonstrated that if the duration of treatment after a first episode of thromboembolism is extended to three to six months, instead of four to six weeks, the rate of recurrence can be reduced, especially among patients with permanent risk factors such as thromboembolism that was idiopathic in nature and venous insufficiency.
1
,
2
The optimal duration of secondary prophylaxis after a second episode of venous thromboembolism is unknown. In one study, patients were stratified according to whether the episode of . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJM199702063360601</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1997-02, Vol.336 (6), p.393-398 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_439112 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Cardiovascular disease Drug therapy Medical sciences Pharmacology. Drug treatments |
| title | The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A39%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Duration%20of%20Oral%20Anticoagulant%20Therapy%20after%20a%20Second%20Episode%20of%20Venous%20Thromboembolism&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Schulman,%20Sam&rft.aucorp=the%20Duration%20of%20Anticoagulation%20Trial%20Study%20Group&rft.date=1997-02-06&rft.volume=336&rft.issue=6&rft.spage=393&rft.epage=398&rft.pages=393-398&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199702063360601&rft_dat=%3Cproquest_swepu%3E11002566%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223972347&rft_id=info:pmid/&rfr_iscdi=true |